Xarelto Lawsuits’ Similarities To Pradaxa Lawsuits Encourage Plaintiffs

XARELTOBloodThinnerHelp.com reports on similarities between Xarelto and Pradaxa lawsuits, which have helped to give plaintiffs involved in current Xarelto lawsuits hope as they pursue justice. Xarelto lawsuit filings have recently exploded. Today, suits filed federally have been consolidated to form multidistrict litigation docket 2592, and number somewhere around 2,000. It has been reported that in the month of August alone, around 400 additional cases joined the MDL, and those involved expect to see these numbers continue to increase.

Xarelto lawsuits are being overseen by Judge Eldon Fallon in the Eastern District of Louisiana, and have been filed against defendants Bayer AG and Janssen Pharmaceuticals, (a division of Johnson & Johnson). These cases are joined by approximately 500 others which have become part of a mass tort grouping in Philadelphia, Pennsylvania.

Bellwether trials

Judge Fallon has asked that a series of four bellwether trials be prepared to go before juries regarding the Xarelto MDL cases. These bellwether trials are currently scheduled for Spring of 2017, as trial preparations need to take place beforehand. The cases contained in the Xarelto MDL all commonly allege that the blood-thinning drug can cause episodes of dangerous, uncontrollable bleeding. In some cases, these bleeding episodes have proven fatal.

Xarelto was released to the market without a corresponding antidote. Much of the controversy surrounding the drug relates to this factor, which plaintiffs call negligent and extremely dangerous. Because it has no antidote, if a patient using Xarelto becomes injured and bleeds, physicians will be unable to get their blood to clot. In these cases, the physicians are required to resort to extreme life-saving tactics such as surgeries to drain pools of blood, or blood transfusions. Patients in these circumstances are at significant risk of losing too much blood, and of either dying or suffering from long-term health issues.

Pradaxa is a similar new-generation blood-thinner which was marketed by Boehringer Ingelheim in October of 2010. Similarly to Xarelto, shortly after its release to market, Pradaxa was surrounded by over 3,500 reports of serious adverse events. More than 750 of these reports involved the death of a Pradaxa patient. Pradaxa quickly became the subject of over 4,000 lawsuits. The evening before the trial was set to begin, however, manufacturer Boehringer Ingelheim agreed to pay $650 million to plaintiffs in Pradaxa lawsuit settlements.

Today, Xarelto plaintiffs view these facts as hopeful as their cases progress toward trial. They await settlement talks, though at this time, there have been no reports of a settlement. As those involved prepare for trial, Attorney Joseph Osborne has been attempting to ensure that everyone negatively affected by Xarelto will have the ability to investigate their legal rights. He is currently offering free legal consultations to those who have taken Xarelto and have suffered from adverse health events after doing so. It is believed that these individuals may be entitled to significant compensation.


Share this Post: